TB-500 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is TB-500?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Wound healing, tissue repair, cardiovascular recovery, neuroprotection, musculoskeletal repair
• Parent Compound: Thymosin beta-4 (TB4), a naturally occurring 43-amino-acid protein
• Molecular Weight: Approximately 887 g/mol (heptapeptide fragment)
• Research Status: Exclusively preclinical; zero completed human clinical trials for TB-500 specifically
• Key Mechanisms: Actin sequestration and cytoskeletal remodeling, VEGF-mediated angiogenesis, NF-kB suppression, Akt/PI3K cell survival signaling
• Published Studies: 150+ preclinical studies; majority conducted on full-length TB4, not TB-500 fragment
• Clinical Trial Status: One Phase I safety trial initiated in 2015 was cancelled; results never published
• Regulatory Classification: Research use only; not approved for human therapeutic application by FDA or comparable agencies
• 2024 Key Finding: Wound-healing activity may be attributable to metabolite Ac-LKKTE rather than the TB-500 parent compound

What is TB-500?

TB-500 is a synthetic heptapeptide representing the active actin-binding segment of thymosin beta-4 (TB4), a naturally occurring protein present in virtually every cell in the human body. The full amino acid sequence of TB-500 is acetyl-leucine-lysine-lysine-threonine-glutamic acid-threonine-glutamine, often abbreviated Ac-LKKTETQ. This seven-amino-acid fragment is considerably smaller than its parent protein, which spans 43 amino acids, and that size difference contributes to its improved bioavailability compared to full-length TB4.

Thymosin beta-4 itself was first isolated from the thymus gland in the 1960s as part of a broader investigation into thymic hormones and immune function. Researchers later discovered that its biological activities extended well beyond immune regulation into tissue repair and cytoskeletal organization. The identification of the LKKTETQ actin-binding domain as the functional core of TB4 led to development of TB-500 as a research tool for studying these repair mechanisms in more tractable form.

An important distinction shapes all TB-500 research: TB-500 is not the same compound as thymosin beta-4. The two share an actin-binding motif, and researchers use this shared structure as the scientific rationale for extrapolating TB4 clinical findings to TB-500. However, this extrapolation remains an assumption rather than validated evidence. Most human clinical trial data in this research area comes from studies using full-length TB4, not the TB-500 fragment. A 2024 metabolite study added another layer of complexity by demonstrating that wound-healing activity previously attributed to TB-500 may actually be driven by a downstream metabolite, Ac-LKKTE, rather than the parent peptide itself.

TB-500 attracts research interest because it targets a fundamental cellular process: the regulation of actin polymerization. Actin is the structural protein cells use to change shape, move toward injury sites, and reorganize tissue during repair. By modulating how cells manage their actin pools, TB-500 influences multiple downstream repair processes simultaneously, making it a broadly applicable research tool across tissue types.

All research on TB-500 is conducted in laboratory and animal model settings. No human therapeutic applications have been established, and the compound is classified for research use only.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

The N-terminal acetylation of the leucine residue is TB-500’s most functionally significant structural feature. This acetyl group shields the N-terminus from peptidase enzymes that would otherwise cleave the peptide from that end, contributing to extended stability in biological environments. Metabolism occurs preferentially from the C-terminus, producing a sequence of shorter fragments as amino acids are sequentially removed from the tail end of the molecule.

The LKKTETQ sequence itself contains the actin-binding domain shared with native thymosin beta-4. This motif binds directly to globular actin (G-actin) monomers, preventing their assembly into filamentous actin (F-actin) networks. The two lysine residues in positions two and three create a positively charged region that facilitates binding to actin’s negatively charged surface. This electrostatic interaction is central to TB-500’s cytoskeletal regulatory activity.

TB-500’s compact seven-amino-acid structure offers research advantages over full-length TB4 beyond bioavailability. Smaller peptides are generally more amenable to chemical synthesis, easier to formulate, and more analytically tractable. The 2024 WADA-funded metabolism study exploited this tractability to characterize TB-500’s full metabolite profile in human liver microsomes, plasma, and serum, identifying Ac-LKKTE as the long-lived active fragment persisting up to 72 hours post-administration.

Mechanisms of Action Being Investigated

TB-500 operates through several interconnected biological pathways. The primary mechanism, actin regulation, drives most downstream effects, but cell survival signaling, angiogenesis, and anti-inflammatory pathways each contribute independently to the repair-promoting profile observed in preclinical studies.

Actin Sequestration and Cytoskeletal Remodeling

TB-500 binds to G-actin monomers, sequestering them from the polymerization process that builds F-actin filaments. By maintaining a larger pool of unpolymerized actin, TB-500 gives cells the flexibility to rapidly reorganize their cytoskeletal architecture in response to injury signals. Cells use actin dynamics to change shape, extend protrusions, and generate the mechanical force needed to move through tissue. TB-500 treatment enhances the migration rates of keratinocytes, fibroblasts, and endothelial cells in culture, consistent with increased cytoskeletal plasticity [1].

This sequestering activity also has implications for cell division. Actin dynamics govern cytokinesis, the final separation of dividing cells, so TB-500’s influence on actin pools extends to proliferation as well as migration. Research models show enhanced recruitment of repair cells to wound sites following TB-500 administration, an effect attributed to this combined migration and proliferation enhancement [2].

No specific cell surface receptor for TB-500 has been identified. Its effects arise from intracellular actin binding and consequent downstream signaling rather than conventional receptor-ligand interactions at the cell membrane.

VEGF Upregulation and Angiogenesis

TB-500 upregulates vascular endothelial growth factor (VEGF) expression in endothelial cells and surrounding tissue. VEGF is the primary driver of new blood vessel formation, and its upregulation by TB-500 promotes endothelial cell sprouting, tube formation, and capillary stabilization. In ischemic tissue models, this angiogenic activity improves oxygen and nutrient delivery to areas deprived of blood supply following injury [3].

The angiogenic effects operate in parallel with actin-mediated migration. Endothelial cells forming new vessels must migrate through tissue and rearrange their shape to create tubular structures, processes that require active cytoskeletal remodeling. TB-500’s dual action on actin dynamics and VEGF expression provides coordinated support for this vessel-building process.

NF-kB Suppression and Anti-Inflammatory Action

TB-500 suppresses activation of NF-kB, the transcription factor that drives expression of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. By reducing NF-kB activity, TB-500 lowers the inflammatory signaling that contributes to tissue damage and impairs healing in acute and chronic injury models [4].

Beyond cytokine suppression, TB-500 shifts macrophage polarization toward the M2 phenotype. M2 macrophages promote tissue remodeling and anti-inflammatory signaling, whereas M1 macrophages drive acute inflammatory responses. The oxidized form of thymosin beta-4, thymosin beta-4 sulfoxide, specifically blocks neutrophil chemotaxis, further reducing inflammatory cell accumulation at injury sites. This multi-level anti-inflammatory action positions TB-500 as a modulator of the repair environment rather than simply a direct repair agent.

Akt/PI3K Cell Survival Signaling

TB-500 activates the Akt/PI3K intracellular signaling pathway, one of the primary mediators of cell survival and proliferation. Akt activation promotes expression of BCL-2, an anti-apoptotic protein that prevents programmed cell death, while simultaneously inhibiting caspase activation. Caspases are the enzymes that execute apoptosis, so their inhibition preserves cells that would otherwise die following injury or oxidative stress [5].

TB-500 also activates ERK1/2 and p38 MAPK pathways, which regulate cellular responses to stress and injury. These pathways stimulate growth factor receptor expression, including hepatocyte growth factor (HGF) receptors, supporting tissue regeneration signaling. The combined anti-apoptotic and pro-survival signaling creates conditions that favor tissue preservation after acute injury.

Cardiac-Specific Mechanisms

In cardiac tissue, TB-500 modulates ROCK1 (Rho-associated protein kinase 1), which regulates cytoskeletal tension and cell movement in cardiac cells. It also modulates miR-139-5p, a microRNA implicated in cardiac remodeling after injury. Preclinical studies show TB-500 reactivates epicardial programs, embryonic-like repair mechanisms in the heart’s outer layer that are normally dormant in adult tissue [6]. Upregulation of chitinase 3-like-1, a mediator associated with tissue repair processes, has been observed in cardiac injury models following TB-500 administration.

Neurological Mechanisms

In nervous system models, TB-500 stimulates oligodendrogenesis, the production of oligodendrocytes that form the myelin sheath protecting nerve fibers. It also supports axonal remodeling, the structural reorganization of nerve connections following injury. These effects, combined with the NF-kB suppression and Akt/PI3K activation described above, create a profile relevant to neuroinflammatory and neurodegenerative research models [7].

Major Areas of Research

TB-500 research spans multiple tissue systems, with musculoskeletal, cardiovascular, neurological, wound healing, and ophthalmic applications each generating significant preclinical literature. The following summaries cover each major area at the level of current evidence.

Wound Healing and Tissue Repair Studies

Wound healing represents the original and most extensively studied application area for thymosin beta-4 and its TB-500 fragment. Rat wound models using topical or systemic TB4 administration showed 42% increased reepithelialization at four days and 61% increased reepithelialization at seven days compared to controls, alongside enhanced collagen deposition [2]. TB-500 administered at 6 mg/kg every three days in animal models accelerated healing and reduced inflammatory markers at wound sites.

The 2024 metabolite study significantly reframed these findings. Researchers demonstrated that the parent compound Ac-LKKTETQ did not itself demonstrate wound-healing activity in laboratory experiments, while the metabolite Ac-LKKTE did. The study authors concluded that reported wound-healing activity in prior literature may be attributable to this metabolite rather than TB-500 itself [8]. This finding does not negate the biological relevance of TB-500 administration but requires that prior studies attributing effects to the parent compound be reinterpreted with metabolite kinetics in mind.

Key Research Highlights:

• 61% increased wound reepithelialization at seven days in rat models using full-length TB4
• Accelerated wound closure and reduced inflammation in TB-500 animal studies
• 2024 evidence implicates metabolite Ac-LKKTE as the active wound-healing agent

Cardiovascular Research Applications

Cardiovascular research constitutes a major focus of TB4 and TB-500 preclinical investigation, with particular attention to myocardial infarction recovery, ischemic injury, and cardiac remodeling. Animal models of myocardial infarction show TB-500 treatment produces reduced infarct size, improved left ventricular contractility, and enhanced neovascularization in damaged cardiac tissue [3,6].

The mechanism involves VEGF upregulation driving new vessel formation in ischemic myocardium alongside epicardial progenitor mobilization. A 2021 review highlighted TB4’s role in reactivating embryonic-like epicardial repair programs in mouse hearts, noting potential relevance to cardiac aging research. Full-length TB4 has reached Phase II human clinical trials for acute myocardial infarction and in congenital heart surgery contexts, with some promising signals reported. These trials used TB4, not TB-500, and results cannot be directly applied to the fragment.

Key Research Highlights:

• Reduced myocardial infarct size and improved contractility in rodent infarction models
• Enhanced neovascularization via VEGF upregulation in ischemic cardiac tissue
• Phase II human trial data for TB4 in cardiac repair; not directly extrapolatable to TB-500

Neurological and Neuroprotection Research

Neurological research on TB-500 and TB4 examines stroke recovery, neuroinflammation, demyelinating disease, and axonal repair. Stroke model studies show optimal dosing administered 24 hours post-stroke improved neurological function scores alongside enhanced oligodendrogenesis and axonal remodeling [7]. Autoimmune encephalomyelitis mouse models using 6 mg/kg across five doses demonstrated reduced inflammatory infiltrates, stimulated myelin-producing cell production, and improved neurological function.

Anti-inflammatory effects through NF-kB suppression and Akt/PI3K-mediated cell survival contribute substantially to neuroprotective outcomes in these models. TB-500 reduces the cytokine burden that drives secondary neurological damage following acute injury and in chronic neuroinflammatory conditions.

A critical limitation applies throughout this research area: no dedicated neuroprotection studies have been conducted specifically on TB-500. All neurological findings are extrapolated from TB4 research or inferred from mechanism studies. Human neurological trials are absent for both compounds.

Key Research Highlights:

• Improved neurological outcomes and enhanced myelination in stroke and encephalomyelitis models
• Reduced neuroinflammation through cytokine suppression and macrophage polarization
• All data extrapolated from TB4; no TB-500-specific neurological studies exist

Musculoskeletal Repair Research

Musculoskeletal research investigates TB-500’s potential in tendon injury, ligament repair, and muscle damage recovery. Animal models indicate TB-500 supports connective tissue healing through its cell migration enhancement and anti-inflammatory action. Researchers have proposed theoretical synergy between TB-500 and BPC-157 for musculoskeletal applications, based on their complementary mechanisms: TB-500 handles cytoskeletal remodeling and cell movement while BPC-157 provides angiogenic growth factor signaling [9].

This synergy hypothesis remains theoretical. No combined clinical trials have been conducted, and the interaction between the two compounds in vivo has not been directly studied. TB4 Phase I safety data in healthy volunteers indicates tolerability relevant to orthopedic and injury contexts, but that study examined safety only, not musculoskeletal efficacy.

Key Research Highlights:

• Enhanced connective tissue repair cell migration in animal injury models
• Theoretical complementary mechanisms with BPC-157 proposed but not experimentally confirmed
• Phase I safety data for TB4 establishes tolerability; no musculoskeletal efficacy data in humans

Ophthalmic Research Applications

Ophthalmic applications represent the most clinically advanced area for thymosin beta-4, though again this data comes from TB4, not TB-500. A Phase II clinical trial of TB4 eye drops for dry eye disease demonstrated a 35% reduction in patient-reported discomfort and a 59% reduction in corneal staining compared to placebo, with the compound rated as safe and well-tolerated throughout the trial [10]. Corneal staining reduction indicates measurable protection of the corneal surface from damage associated with dry eye disease.

Preclinical models show low apoptosis rates in toxin-exposed corneas treated with TB4, consistent with the anti-apoptotic mechanisms described in other tissue systems. The ophthalmic findings represent the strongest human clinical evidence base in this research space, though extrapolation to TB-500 requires the same caveats applied throughout: shared actin-binding sequence does not guarantee identical clinical activity between parent and fragment.

Key Research Highlights:

• 35% discomfort reduction and 59% corneal staining reduction in Phase II TB4 dry eye trial
• Safe and well-tolerated profile in the ophthalmic clinical study
• Data applies to full-length TB4; TB-500-specific ophthalmic research has not been conducted

Metabolic and Inflammatory Conditions Research

Exploratory research has examined TB-500 in metabolic syndrome contexts, including non-alcoholic fatty liver disease (NAFLD) and endothelial function in diabetes models. Endothelial cell protection through anti-apoptotic signaling and improved vascular function via VEGF upregulation provides mechanistic rationale for metabolic disease applications. Research in this area remains at an early exploratory stage. No substantial efficacy findings have been reported, and the mechanistic basis for investigation is largely inferred from cardiovascular and anti-inflammatory data rather than direct metabolic disease studies.

Key Research Highlights:

• Proposed relevance to NAFLD research based on hepatocyte protection mechanisms
• Endothelial function improvement in diabetic animal models
• Research at early exploratory stage; no substantial efficacy findings reported

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

TB-500’s N-terminal acetylation provides stability against N-terminal peptidase enzymes, extending its biological half-life compared to non-acetylated peptides. The smaller molecular size of TB-500 relative to full-length TB4 improves bioavailability. Systemic distribution following injection has been confirmed in animal studies across subcutaneous, intraperitoneal, and intravenous routes.

Oral bioavailability for TB-500 has not been established. Most research uses injectable administration to ensure systemic delivery. The peptide’s water solubility supports formulation in standard aqueous buffers for research applications.

Distribution and Metabolism

TB-500 distributes systemically following administration, with preferential accumulation in areas of active tissue injury or inflammation. This targeting behavior relates to increased vascular permeability at injury sites and upregulated cellular uptake in damaged tissue. The peptide has been detected in cardiac tissue, wound sites, and neural tissue in preclinical studies, consistent with its proposed repair applications.

Metabolism proceeds through sequential C-terminal cleavage, with amino acids removed from the tail end of the peptide in stepwise fashion. The N-terminal acetyl group protects the leucine residue at the opposite end from this degradation pathway. A WADA-funded metabolism study characterized this process using human liver microsomes, S9 fractions, human plasma, and human serum, identifying the major metabolite pathway and producing quantitative kinetics data [8].

Metabolite Kinetics

Two metabolites dominate the post-administration profile in human biological matrices. The primary early metabolite, Ac-LK (acetyl-leucine-lysine), reaches peak concentrations during the 0 to 6 hour window, representing rapid initial catabolism of the parent compound. The longer-lived metabolite, Ac-LKKTE, persists up to 72 hours post-administration at detectable concentrations.

The identification of Ac-LKKTE as the wound-healing-active fragment has significant implications for understanding TB-500’s pharmacological timeline. Biological effects observed hours to days after administration may reflect metabolite activity rather than parent compound action. This metabolite persistence may partially explain why preclinical wound healing studies observed sustained effects despite the shorter stability of the parent peptide.

Delivery Methods Under Investigation

• Subcutaneous injection: The most common route in animal studies; confirmed systemic distribution with reasonable bioavailability
• Intraperitoneal injection: Standard in rodent research models; produces rapid systemic exposure
• Intravenous injection: Used in some cardiovascular studies for immediate systemic delivery
• Topical application: Studied in wound healing and ophthalmic models; TB4 eye drops used in Phase II dry eye trial

Excretion and Clearance

TB-500 and its metabolites undergo clearance through standard peptide degradation pathways, with final excretion via renal filtration. The 72-hour persistence of the Ac-LKKTE metabolite in human biological matrices extends the analytical detection window considerably beyond the parent compound’s clearance timeline. WADA doping control laboratories have integrated these metabolite kinetics into urine screening methods, enabling detection based on metabolite presence rather than parent compound levels alone.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

The most fundamental limitation in TB-500 research is the near-complete absence of human clinical evidence. No completed Phase II or Phase III human clinical trials exist for TB-500. The only Phase I safety trial initiated for TB-500 specifically, begun in 2015, was cancelled by the sponsoring organization before completion. Results were never submitted or published. Medical commentators have noted this cancellation as a significant red flag, as unexplained trial cancellations often reflect safety or tolerability findings that the sponsor chose not to disclose.

Human clinical trial data from full-length TB4 studies cannot be directly applied to TB-500. The two compounds share an actin-binding sequence but differ substantially in molecular size, pharmacokinetics, and metabolite profiles. The 2024 finding that TB-500’s wound-healing activity may be mediated by a metabolite further complicates any extrapolation from TB4 studies, since TB4 and TB-500 would produce different metabolite profiles.

Mechanistic Understanding

The 2024 metabolite study fundamentally challenges interpretations of prior TB-500 research. Studies that attributed wound-healing and repair effects to the parent Ac-LKKTETQ compound may have been observing metabolite activity. This does not invalidate prior findings but requires that all mechanism-of-action claims be revisited in light of metabolite pharmacology. The active mechanisms of Ac-LKKTE specifically have not been characterized in detail.

Methodological Considerations

The majority of TB-500 research uses animal models, primarily rodent studies. Interspecies differences in peptide metabolism, receptor biology, and tissue repair kinetics limit direct translation of animal findings to human biology. Most neurological and musculoskeletal data extrapolated to TB-500 was actually generated using full-length TB4, adding a second layer of extrapolation to the species translation challenge.

Areas Needing Further Investigation

• Human pharmacokinetic and safety profiling for TB-500 specifically: the foundational missing data before any human application can be considered
• Characterization of Ac-LKKTE mechanism of action: the active metabolite’s biological targets and potency remain incompletely described
• Long-term safety in animal models beyond 30-day treatment periods: chronic administration effects are unstudied
• Direct comparative studies of TB-500 versus full-length TB4: needed to quantify the extent to which fragment findings replicate parent protein findings
• Drug interaction profile: TB-500’s interactions with common medications or other research compounds have not been investigated

Regulatory and Research Status

Current Classification

FDA Status

TB-500 is classified as an unapproved new drug by the FDA and is not approved for human therapeutic use. The compound is available for legitimate laboratory research purposes under applicable regulations. The FDA has not issued compound-specific guidance for TB-500, and no new drug application has been submitted for the fragment. The cancelled Phase I trial represents the closest approach to formal regulatory engagement for TB-500 specifically, and the lack of published results from that trial leaves the FDA-facing safety data set empty.

WADA Status

WADA prohibits TB-500 in competitive athletics. The compound appears on the prohibited list under peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping testing must not use TB-500 regardless of administration route or timing relative to competition. WADA’s funded metabolism research has produced urine detection methods targeting both the TB-500 parent compound and its long-lived Ac-LKKTE metabolite, extending the detection window to at least 72 hours post-administration [8].

International Perspective

Most major regulatory jurisdictions follow classifications parallel to the FDA. The European Medicines Agency has not approved TB-500 or full-length TB4 for human therapeutic use. Both compounds are classified as research chemicals in major international research markets. Veterinary regulatory status varies by jurisdiction, with some markets permitting limited veterinary research applications.

Research Community Approach

Legitimate TB-500 research takes place within academic and pharmaceutical laboratory settings under institutional oversight. Research protocols require appropriate biosafety measures and must comply with applicable animal use and research chemical regulations. The compound’s well-characterized mechanism and tractable structure make it a useful research tool for studying cytoskeletal biology and tissue repair processes independent of any clinical application ambitions.

Future Research Directions

The 2024 metabolite findings create a logical next step for the field: dedicated studies characterizing the mechanism and potency of Ac-LKKTE, potentially followed by its development as an independent research compound. If Ac-LKKTE proves to be the pharmacologically active species, drug development logic would favor working directly with the active metabolite rather than a prodrug precursor. Human pharmacokinetic and safety studies for TB-500 remain the prerequisite for any clinical development pathway, though the cancelled 2015 Phase I trial introduces uncertainty about what findings might have blocked that path.

Key Research Findings

Wound Reepithelialization in Rat Models

Research Focus: Acceleration of wound reepithelialization and collagen deposition using TB4 in rat full-thickness wound models Key Results: 42% increase in reepithelialization at four days and 61% increase at seven days versus controls; enhanced collagen deposition and organized tissue architecture at wound sites Significance: Establishes the magnitude of wound healing acceleration achievable through thymosin beta-4 pathway activation; provides quantitative benchmarks for comparing intervention effects Limitations: Full-length TB4 used, not TB-500 fragment; rat wound biology differs from human wound healing; 2024 metabolite findings suggest these effects may be mediated by a metabolite rather than the administered compound [2,8]

2024 Metabolite Activity Discovery

Research Focus: Characterization of TB-500 metabolites and identification of the wound-healing-active species Key Results: Parent compound Ac-LKKTETQ did not demonstrate wound-healing activity in laboratory experiments; metabolite Ac-LKKTE demonstrated wound-healing activity; metabolite persists up to 72 hours in human biological matrices Significance: Fundamentally reframes understanding of how TB-500 exerts its biological effects; requires reinterpretation of prior research attributing activity to parent compound; has practical implications for drug development strategy and doping detection Limitations: Study conducted in vitro and in human biological matrices; in vivo validation of metabolite-mediated activity in intact organisms needed [8]

Cardiac Recovery in Myocardial Infarction Models

Research Focus: TB-500 effects on cardiac function and tissue preservation following experimental myocardial infarction in rodents Key Results: Reduced infarct size, improved left ventricular contractility, enhanced neovascularization in damaged myocardium; upregulation of chitinase 3-like-1 and modulation of ROCK1 and miR-139-5p observed Significance: Establishes multi-mechanism cardiac repair profile with translational potential; VEGF-driven neovascularization addresses the ischemic core of post-infarction damage Limitations: Rodent model; human cardiac physiology differs substantially from mouse and rat models; no human cardiac efficacy data exists for TB-500 [3,6]

Phase II Dry Eye Trial for TB4

Research Focus: Efficacy and safety of full-length TB4 eye drops in patients with moderate to severe dry eye disease Key Results: 35% reduction in patient-reported discomfort versus placebo; 59% reduction in corneal staining versus placebo; safe and well-tolerated throughout the trial Significance: Represents the strongest human clinical evidence involving thymosin beta-4 pathway activation; demonstrates that the compound class can produce measurable, patient-relevant outcomes at the human clinical level Limitations: Conducted with full-length TB4, not TB-500 fragment; cannot be directly extrapolated to TB-500; results from this specific trial have not been followed by regulatory approval [10]

Autoimmune Encephalomyelitis Neurological Outcomes

Research Focus: TB4 treatment effects in mouse autoimmune encephalomyelitis, a model for multiple sclerosis-like demyelinating disease Key Results: Dosing at 6 mg/kg across five doses reduced inflammation, stimulated oligodendrogenesis, enhanced neurological function scores, and reduced inflammatory infiltrates in neural tissue Significance: Establishes biological plausibility for thymosin beta-4 pathway modulation in demyelinating disease contexts; the oligodendrogenesis effect addresses myelin repair, which is a central therapeutic target in demyelinating conditions Limitations: Mouse model; conducted using full-length TB4; no neurological human trials for either TB4 or TB-500; results not reproduced in human tissue [7]

Phase I Safety Profile for TB4 in Healthy Volunteers

Research Focus: Safety and tolerability of recombinant full-length TB4 administered intravenously at single and multiple doses in healthy human subjects Key Results: 84 healthy volunteers received TB4 without dose-limiting toxicity, serious adverse events, or drug accumulation; well-tolerated across the dose range tested Significance: Provides the best available human safety signal for compounds acting through the thymosin beta-4 pathway; establishes that systemic administration of a related compound is tolerable in humans at the doses tested Limitations: Applies to full-length TB4, not TB-500 fragment; Phase I establishes safety only, not efficacy; the cancelled TB-500-specific Phase I trial means analogous data for the fragment itself does not exist [11]

Frequently Asked Questions

What is TB-500 and how does it differ from thymosin beta-4?

TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4, a protein that occurs naturally throughout the body. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only the portion responsible for binding to actin, a key structural protein in cells. The two compounds share this actin-binding sequence, but they are not the same molecule, and most human clinical research has been conducted on full-length thymosin beta-4 rather than the TB-500 fragment.

What does TB-500 do in research studies?

In preclinical research, TB-500 has been investigated for its effects on tissue repair, wound healing, cardiovascular recovery, and neuroprotection. Its primary action involves regulating how cells manage actin, their internal structural protein, which influences cell movement, shape change, and migration toward injury sites. Studies also show anti-inflammatory effects and promotion of new blood vessel formation in animal models, though a 2024 study suggests these wound-healing effects may be caused by a breakdown product of TB-500 rather than the compound itself.

Has TB-500 been tested in humans?

No completed human clinical trials exist for TB-500 specifically. A Phase I safety trial was initiated in 2015 but was cancelled by the sponsor before completion, and those results were never published. Human clinical data in this research area comes from studies using full-length thymosin beta-4, which is a related but distinct compound. That fuller protein has reached Phase II trials for dry eye disease, wound healing, and cardiac repair, but those results cannot be directly applied to the TB-500 fragment.

Is TB-500 prohibited in competitive sports?

Yes. WADA prohibits TB-500 in competitive athletics and lists it under peptide hormones, growth factors, related substances, and mimetics. WADA has funded metabolism research on TB-500 specifically, and its doping control laboratories have developed urine detection methods that can identify both the parent compound and its active metabolite, Ac-LKKTE, which persists in the body for up to 72 hours after administration.

What is the significance of the 2024 TB-500 metabolite research?

A 2024 study found that TB-500’s parent compound did not itself demonstrate wound-healing activity in laboratory experiments, while one of its breakdown products, a shorter fragment called Ac-LKKTE, did demonstrate that activity. This finding suggests that much of the biological activity previously attributed to TB-500 may actually be produced by the compound’s metabolites rather than TB-500 itself. This reshapes how researchers interpret prior studies and points toward the active metabolite as the potentially important species for future investigation.

References

1. Sosne, G., Qiu, P., Goldstein, A.L., & Wheater, M. (2010). Biological activities of thymosin beta4 defined by active sites in actin and non-actin binding domains. FASEB Journal, 24(7), 2144-2151. PubMed

2. Philp, D., Nguyen, M., Scheremeta, B., St-Surin, S., Villa, A.M., Bhattacharya, A., Kleinman, H.K., & Elkin, M. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal, 18(2), 385-387. PubMed

3. Smart, N., Risebro, C.A., Melville, A.A., Moses, K., Bhatt, D.L., Bhatt, A., & Riley, P.R. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177-182. PubMed

4. Qiu, P., Wheater, M.K., Qiu, Y., & Sosne, G. (2011). Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, corneal epithelial apoptosis, and preserves corneal epithelial migration. FASEB Journal, 25(4), 1356-1363. PubMed

5. Bock-Marquette, I., Saxena, A., White, M.D., Dimaio, J.M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466-472. PubMed

6. Hsieh, P.C., Davis, M.E., Lisowski, L.K., & Lee, R.T. (2006). Endothelial-cardiomyocyte interactions in cardiac development and repair. Annual Review of Physiology, 68, 51-66. PubMed

7. Morris, D.C., Chopp, M., Zhang, L., Lu, M., & Zhang, Z.G. (2010). Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience, 169(2), 674-682. PubMed

8. Thevis, M., Kohler, M., Thomas, A., & Schanzer, W. (2024). Characterization of TB-500 metabolites in human biological matrices and implications for doping control. Drug Testing and Analysis, 16(3), 245-256. PubMed

9. Brcic, L., Brcic, I., Staresinic, M., Novinscak, T., Sikiric, P., & Seiwerth, S. (2009). Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology, 60(7), 191-196. PubMed

10. Sosne, G., Szliter, E.A., Barrett, R., Kernacki, K.A., Kleinman, H., & Hazlett, L.D. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research, 74(2), 293-299. PubMed

11. Ruff, D., Crockford, D., Girardi, G., & Zhang, Y. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences, 1194, 223-229. PubMed

12. Goldstein, A.L., Hannappel, E., Sosne, G., & Kleinman, H.K. (2012). Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51. PubMed

13. Badamchian, M., Fagarasan, M.O., Danner, R.L., Suffredini, A.F., Damaraj, R., & Goldstein, A.L. (2003). Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. International Immunopharmacology, 3(8), 1225-1233. PubMed

14. Philp, D., Huff, T., Gho, Y.S., Hannappel, E., & Kleinman, H.K. (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal, 17(14), 2103-2105. PubMed

15. Sosne, G., Qiu, P., Christopherson, P.L., & Wheater, M.K. (2007). Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Experimental Eye Research, 84(4), 663-669. PubMed

16. Gupta, S., Mishra, K., Surolia, A., & Bhattacharya, S. (2010). Thymosin beta4 promotes the differentiation of neural progenitor cells into neurons and astrocytes. Indian Journal of Biochemistry and Biophysics, 47(3), 135-143. PubMed

17. Crockford, D., Turjman, N., Allan, C., & Angel, J. (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 1194, 179-189. PubMed